[A Case Report of Primary Pulmonary Synovial Sarcoma with Postoperative Multiple Metastases Treated with Apatinib].

Primary pulmonary synovial sarcoma is a rare pulmonary malignant tumor originated from primitive mesenchymal, which has short overall survival and poor prognosis. Related case reports are lacked at home and abroad. In recent years, the development of targeted therapy has brought remarkable benefits to cancer patients. Apatinib (Hengrui Pharmaceutical Co. Ltd, Jiangsu, People's Republic of China) is a small molecule vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, which selectively inhibits VEGFR-2 and blocks the VEGF signal pathway, then strongly inhibiting the tumor angiogenesis. Apatinib has shown favorable therapeutic effect and acceptable toxicity on various tumors. Here we report a case of primary pulmonary synovial sarcoma with postoperative multiple metastases treated with apatinib, in order to provide a new considerable treatment. .【中文题目：阿帕替尼治疗肺原发性滑膜肉瘤 术后多发转移1例】 【中文摘要：原发性肺滑膜肉瘤是一种起源于原始间叶细胞的罕见肺部恶性肿瘤，其临床特点包括生存期短、预后差，目前国内外仅有少数相关报道。近年来，靶向治疗的发展为肿瘤患者带来显著的获益。甲磺酸阿帕替尼是我国自主研发的小分子血管内皮生长因子受体-2（vascular endothelial growth factor receptor-2, VEGFR-2）抑制剂，可高度选择性地抑制VEGFR-2酪氨酸激酶活性，阻断血管内皮生长因子（vascular endothelial growth factor, VEGF）结合后的信号通路，从而强效抑制肿瘤血管的生成，目前已在多种瘤种中显示出确切的抗肿瘤效果和可接受的毒副反应。本文介绍了阿帕替尼治疗原发性肺滑膜肉瘤术后多发转移1例，以期在临床工作中为医生提供新的治疗思路。 】 【中文关键词：甲磺酸阿帕替尼；肺肿瘤；原发性肺滑膜肉瘤】.